Amgen (NASDAQ:AMGN) Stock Rating Lowered by Leerink Partnrs

Amgen (NASDAQ:AMGNGet Free Report) was downgraded by Leerink Partnrs from an “outperform” rating to a “market perform” rating in a research note issued to investors on Wednesday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Amgen’s FY2028 earnings at $20.92 EPS.

Other equities research analysts have also issued reports about the company. Jefferies Financial Group restated a “buy” rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, October 12th. The Goldman Sachs Group lifted their price target on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday. Truist Financial restated a “buy” rating and set a $320.00 price target on shares of Amgen in a research report on Wednesday, November 29th. Deutsche Bank Aktiengesellschaft began coverage on Amgen in a research report on Thursday, November 9th. They set a “hold” rating and a $240.00 price target on the stock. Finally, Oppenheimer restated an “outperform” rating and set a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $295.30.

Get Our Latest Stock Analysis on AMGN

Amgen Price Performance

Shares of AMGN stock opened at $294.85 on Wednesday. The firm has a market cap of $157.80 billion, a P/E ratio of 23.61, a P/E/G ratio of 2.84 and a beta of 0.62. Amgen has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The business’s 50 day moving average price is $294.92 and its 200-day moving average price is $273.81. The company has a debt-to-equity ratio of 7.71, a quick ratio of 2.56 and a current ratio of 2.86.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 152.15% and a net margin of 23.83%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same period last year, the company earned $4.09 EPS. On average, equities research analysts anticipate that Amgen will post 19.81 earnings per share for the current year.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,096 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $273.03, for a total value of $572,270.88. Following the completion of the transaction, the senior vice president now owns 10,874 shares in the company, valued at $2,968,928.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.46% of the company’s stock.

Institutional Trading of Amgen

Hedge funds have recently bought and sold shares of the company. Briaud Financial Planning Inc purchased a new stake in Amgen during the third quarter valued at $26,000. BOK Financial Private Wealth Inc. bought a new stake in Amgen during the fourth quarter valued at about $29,000. OFI Invest Asset Management bought a new stake in Amgen during the third quarter valued at about $26,000. Planned Solutions Inc. bought a new stake in Amgen during the fourth quarter valued at about $30,000. Finally, Delos Wealth Advisors LLC grew its holdings in Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 100 shares during the period. Hedge funds and other institutional investors own 74.44% of the company’s stock.

Amgen Company Profile

(Get Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.